Mairs and Power's BMY Position Overview
Mairs and Power (via Mairs & Power INC) currently holds 26,392 shares of Bristol-Myers Squibb Company (BMY) worth $1.19 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Mairs and Power has maintained a long-term strategic position in BMY, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2016, adding 45,074 shares. Largest reduction occurred in Q1 2020, reducing 73,844 shares.
Analysis based on 13F filings available since 2013 Q2
Mairs and Power's Bristol-Myers Squibb Company (BMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bristol-Myers Squibb Company (BMY) Trades by Mairs and Power
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +327,257 | Add 0.00% | 327,256 | $44.69 |
| Q3 2013 | -22,300 | Reduce 6.81% | 304,956 | $46.28 |
| Q4 2013 | -4,200 | Reduce 1.38% | 300,756 | $53.15 |
| Q1 2014 | -3,917 | Reduce 1.30% | 296,839 | $51.95 |
| Q2 2014 | -3,300 | Reduce 1.11% | 293,539 | $48.51 |
| Q3 2014 | +896 | Add 0.31% | 294,435 | $51.18 |
| Q4 2014 | +600 | Add 0.20% | 295,035 | $59.03 |
| Q1 2015 | -1,265 | Reduce 0.43% | 293,770 | $64.50 |
| Q2 2015 | -10,787 | Reduce 3.67% | 282,983 | $66.54 |
| Q3 2015 | +1,591 | Add 0.56% | 284,574 | $59.20 |
| Q4 2015 | +2,489 | Add 0.87% | 287,063 | $68.79 |
| Q1 2016 | -1,145 | Reduce 0.40% | 285,918 | $63.88 |
| Q2 2016 | -170 | Reduce 0.06% | 285,748 | $73.55 |
| Q3 2016 | +45,074 | Add 15.77% | 330,822 | $53.92 |
| Q4 2016 | +10,000 | Add 3.02% | 340,822 | $58.44 |
| Q1 2017 | +3,458 | Add 1.01% | 344,280 | $54.38 |
| Q2 2017 | -1,237 | Reduce 0.36% | 343,043 | $55.72 |
| Q3 2017 | -3,198 | Reduce 0.93% | 339,845 | $63.74 |
| Q4 2017 | -7,253 | Reduce 2.13% | 332,592 | $61.28 |
| Q1 2018 | -40,690 | Reduce 12.23% | 291,902 | $63.25 |
| Q2 2018 | -12,958 | Reduce 4.44% | 278,944 | $55.34 |
| Q3 2018 | -22,413 | Reduce 8.03% | 256,531 | $62.08 |
| Q4 2018 | -1,175 | Reduce 0.46% | 255,356 | $51.98 |
| Q1 2019 | -6,000 | Reduce 2.35% | 249,356 | $47.71 |
| Q2 2019 | -11,824 | Reduce 4.74% | 237,532 | $45.35 |
| Q3 2019 | -8,350 | Reduce 3.52% | 229,182 | $50.71 |
| Q4 2019 | -6,725 | Reduce 2.93% | 222,457 | $64.19 |
| Q1 2020 | -73,844 | Reduce 33.19% | 148,613 | $55.74 |
| Q2 2020 | -36,341 | Reduce 24.45% | 112,272 | $58.80 |
| Q3 2020 | -4,372 | Reduce 3.89% | 107,900 | $60.29 |
| Q4 2020 | -4,026 | Reduce 3.73% | 103,874 | $62.03 |
| Q1 2021 | -6,522 | Reduce 6.28% | 97,352 | $63.13 |
| Q2 2021 | -14,717 | Reduce 15.12% | 82,635 | $66.82 |
| Q3 2021 | -5,530 | Reduce 6.69% | 77,105 | $59.17 |
| Q4 2021 | -6,666 | Reduce 8.65% | 70,439 | $62.35 |
| Q1 2022 | -1,668 | Reduce 2.37% | 68,771 | $73.02 |
| Q2 2022 | -832 | Reduce 1.21% | 67,939 | $77.00 |
| Q3 2022 | +11,738 | Add 17.28% | 79,677 | $71.09 |
| Q4 2022 | -570 | Reduce 0.72% | 79,107 | $71.95 |
| Q1 2023 | -1,082 | Reduce 1.37% | 78,025 | $69.31 |
| Q2 2023 | -16,242 | Reduce 20.82% | 61,783 | $63.95 |
| Q3 2023 | -11,681 | Reduce 18.91% | 50,102 | $58.04 |
| Q4 2023 | +3,200 | Add 6.39% | 53,302 | $51.31 |
| Q1 2024 | -6,805 | Reduce 12.77% | 46,497 | $54.23 |
| Q2 2024 | -17,115 | Reduce 36.81% | 29,382 | $41.53 |
| Q3 2024 | -3,400 | Reduce 11.57% | 25,982 | $51.74 |
| Q4 2024 | +180 | Add 0.69% | 26,162 | $56.56 |
| Q1 2025 | +398 | Add 1.52% | 26,560 | $60.99 |
| Q2 2025 | +282 | Add 1.06% | 26,842 | $46.29 |
| Q3 2025 | -450 | Reduce 1.68% | 26,392 | $45.10 |
Mairs and Power's Bristol-Myers Squibb Company Investment FAQs
Mairs and Power first purchased Bristol-Myers Squibb Company (BMY) in Q2 2013, acquiring 327,256 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power has held Bristol-Myers Squibb Company (BMY) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power's largest addition to Bristol-Myers Squibb Company (BMY) was in Q2 2013, adding 327,256 shares worth $14.62 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Mairs and Power's firm, Mairs & Power INC, owns 26,392 shares of Bristol-Myers Squibb Company (BMY), valued at approximately $1.19 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bristol-Myers Squibb Company (BMY) represents approximately 0.01% of Mairs and Power's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power's peak holding in Bristol-Myers Squibb Company (BMY) was 344,280 shares, as reported at the end of Q1 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.